Parexel shares down as concerns over low bookings remain

By Zachary Brennan

- Last updated on GMT

Parexel shares remained lower after a bookings fall off
Parexel shares remained lower after a bookings fall off

Related tags: Revenue

CRO Parexel’s stock fell to a four-month low and continued to hover around that level late last week following concerns about low bookings and increased competition in the first quarter of 2014.

Bookings fell to $394m in Q1, which was down from $481m a year earlier, the company said. Baird & Co analysts said the bookings were about 30% below their expectations, according to Reuters​.

Part of the issue may stem from Merck, which accounted for 12% of Parexel's consolidated service revenue in FY 2013, and which said earlier this month it would cut about 4,000 R&D jobs.

But Josef von Rickenbach in the conference call with analysts last week said that the fall off in bookings might just be the result of companies pushing back their bookings to the second quarter.

Probably the single biggest factor that ultimately led to the lower bookings was the fact that a significant portion of the decisions for proposals moved out of the quarter into the second quarter. In fact, I'd say that's the single biggest contributing factor​,” von Rickenbach said, according to a transcript​ of the call.

He added that “so far in the quarter, which is to say in October, we've had a relatively good success and a good win rate​.” 

Despite the question marks regarding competition, Parexel saw almost 14% revenue growth for the quarter compared to the previous year. Parexel also basically maintained its FY 2014 guidance, calling for $1.95-$2.11 in EPS, and $1.89 billion to $1.92 billion in revenue.

As far investor analysts, those at Robert W. Baird downgraded shares of Parexel while analysts at Sterne Agee reiterated an underperform rating, according to Ticker Report​.

The report added that one investment analyst has rated the stock with a sell rating, seven have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating. The stock presently has a consensus rating of “hold” and a consensus target price of $49.88.

Von Rickenbach also stressed that the company held its own among the smaller and emerging companies looking to outsource. “We have said many times that the awards from strategic clients can be somewhat lumpy…Finally, we actually had relatively good opportunities from small and emerging companies... In this particular quarter, that turned out to be particularly competitive and we held our line in terms of economics​,” he said.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

Related suppliers

Follow us


View more